OTCM
HBRM
Market cap10kUSD
Jul 09, Last price
0.00USD
1D
9,900.00%
1Q
9,900.00%
Jan 2017
0.00%
Name
Herborium Group Inc
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Herborium Group, Inc. operates as a specialized firm in botanical therapeutics, focusing on the creation, licensing, and commercialization of its unique, plant-based medicinal goods for both general consumers and healthcare professionals. Its product range includes dermatological solutions like AcnEase, an herbal treatment designed to alleviate symptoms associated with hormonal acne and various forms of Rosacea. The company also offers the AcnEase Skin Management System, intended to diminish acne marks and scars. Furthermore, Herborium provides non-prescription sexual health and performance products. These serve as alternatives for specific sexual dysfunctions that may arise from cardiovascular conditions, the use of antidepressants, or surgical procedures such as hysterectomies. The company also offers energy-boosting products, notably Lasting Energy. This herbal supplement aims to reduce hangover effects, counteract jet lag, and address general energy depletion caused by intense physical activities, high stress levels, prolonged sexual engagements, or other enduring or temporary physical demands. Additional products in its portfolio include the Liver Activator Series for managing liver damage; ProstAid, a natural remedy specifically formulated for Benign Prostate Hyperplasia (BPH); and CardioVitae, a fermentation-based product utilizing a Lucidium-derived cell line to target cardio-pulmonary insufficiencies. Herborium Group, Inc. distributes its products across the United States, the United Kingdom, and mainland Europe, utilizing a network of distributors, specialty retailers, and its e-commerce platform. The company was founded in 2000 and has its principal office located in Fort Lee, New Jersey.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑11 | 2024‑11 | 2023‑11 | 2022‑11 | 2021‑11 | 2020‑11 | 2019‑11 | 2018‑11 | 2017‑11 | 2016‑11 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||